Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q2 2024 Earnings Call Transcript August 12, 2024Esperion Therapeutics, Inc. misses on earnings expectations.
Esperion Therapeutics Inc. (ESPR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 30,000,000 | $27,675,124 | 0.56% | ||
| 2. | 26,000,000 | $24,050,000 | +41% | 0.76% | |
| 3. | 23,850,000 | $22,001,723 | +42% | 0.62% | |
| 4. | 20,315,000 | $18,816,769 | 3.05% | ||
| 5. | Millennium Management Israel Englander | 6,513,932 | $14,460,929 | +15% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.57 | 23,091 | Director | 36,500 | 2023-05-11 | Filing | |
| $1.49 | 8,409 | Director | 13,409 | 2023-05-10 | Filing | |
| $1.50 | 8,111 | Director | 8,111 | 2023-05-10 | Filing | |
| $1.26 | 20,000 | Officer, Director | 312,816 | 2023-05-09 | Filing | |
| $7.46 | 1,000 | Officer | 54,024 | 2022-08-31 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.95 | 211 | Officer | 165,267 | 2024-08-19 | Filing | |
| $2.59 | 108 | Officer | 165,478 | 2024-07-17 | Filing | |
| $2.60 | 917 | Officer | 272,862 | 2024-07-17 | Filing | |
| $2.87 | 3,285 | Officer | 273,779 | 2024-06-18 | Filing | |
| $2.86 | 2,540 | Officer | 165,586 | 2024-06-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 41,029,000 | $32,542,716 | 10.6% | |
| 2. | 8,891,103 | $26,584,398 | 0.14% | |
| 3. | 5,137,750 | $15,361,873 | 0% | |
| 4. | 4,204,264 | $12,570,749 | 0.19% | |
| 5. | 3,791,300 | $11,335,987 | 14.16% |
News See All
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q1 2024 Earnings Call Transcript
Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.00032, expectations were $-0.17.
11 Best Low Price Pharma Stocks To Invest In
In this piece, we will take a look at the 13 best low price pharma stocks to invest in.
5 Best Small Cap Pharma Stocks to Invest In
In this piece, we will take a look at the five best small cap pharma stocks to invest in.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript
Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.5, expectations were $-0.53. Esperion Therapeutics, Inc.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript
Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.5, expectations were $-0.53. Esperion Therapeutics, Inc.
12 Best Medical Stocks to Buy Under $10
In this article, we will take a look at the 12 best medical stocks to buy under $10.
Should You Sell Esperion Therapeutics (ESPR)?
Tourlite Capital Management, an investment management firm, released its fourth quarter 2023 investor letter, a copy of which can be downloaded here.
5 Hot Penny Stocks To Buy According to Hedge Funds
Qurate Retail Inc. (NASDQ:QRTEA) shares have gained about 38% over the past one month. It ranks 5th in our list of the hot penny stocks to buy according to hedge funds.
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by and welcome to Esperion Therapeutics Third Quarter 2023 financial results call. At this time, all participants are in a lisen-only mode.
Billionaire Hedge Funds
